Key Points
- CEO Martine Rothblatt sold 9,500 shares at an average price of $574.86 for a total of $5,461,170, reducing her position by 19% to 40,513 shares (about $23.29M).
- Q4 results: EPS beat but revenue missed — United Therapeutics reported $7.70 EPS vs. $6.78 expected, while revenue was $790.2M versus $814.8M consensus; the company posted a 41.94% net margin and 19.3% ROE.
- Analysts remain generally positive with multiple price-target increases and an average rating of "Moderate Buy" and an average price target of $601.50; the stock has a $25.36B market cap and is trading near its 52‑week high.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, April 13th. The shares were sold at an average price of $574.86, for a total transaction of $5,461,170.00. Following the completion of the transaction, the chief executive officer owned 40,513 shares in the company, valued at approximately $23,289,303.18. This trade represents a 19.00% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
United Therapeutics Stock Up 0.2%
UTHR stock opened at $578.54 on Wednesday. The company has a market cap of $25.36 billion, a price-to-earnings ratio of 20.74, a PEG ratio of 1.64 and a beta of 0.75. The business has a fifty day simple moving average of $520.74 and a 200-day simple moving average of $487.07. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $607.89.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share for the quarter, beating analysts' consensus estimates of $6.78 by $0.92. The firm had revenue of $790.20 million for the quarter, compared to analysts' expectations of $814.80 million. United Therapeutics had a return on equity of 19.30% and a net margin of 41.94%.The firm's revenue for the quarter was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $6.19 earnings per share. As a group, analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.
Analyst Ratings Changes
A number of analysts have recently issued reports on UTHR shares. TD Cowen boosted their target price on United Therapeutics from $575.00 to $660.00 and gave the stock a "buy" rating in a report on Monday, March 30th. Royal Bank Of Canada lifted their price target on shares of United Therapeutics from $587.00 to $643.00 and gave the company an "outperform" rating in a research report on Thursday, February 26th. Cantor Fitzgerald boosted their price objective on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an "overweight" rating in a research note on Thursday, March 12th. Morgan Stanley increased their price objective on shares of United Therapeutics from $471.00 to $519.00 and gave the stock an "equal weight" rating in a research report on Friday. Finally, Oppenheimer raised their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, February 26th. Ten analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $601.50.
View Our Latest Analysis on UTHR
Institutional Investors Weigh In On United Therapeutics
Several hedge funds have recently modified their holdings of UTHR. AE Wealth Management LLC boosted its stake in shares of United Therapeutics by 396.3% in the third quarter. AE Wealth Management LLC now owns 4,288 shares of the biotechnology company's stock valued at $1,798,000 after purchasing an additional 3,424 shares during the period. Great Lakes Advisors LLC increased its stake in United Therapeutics by 194.7% during the 3rd quarter. Great Lakes Advisors LLC now owns 4,503 shares of the biotechnology company's stock worth $1,888,000 after buying an additional 2,975 shares during the period. Optimize Financial Inc purchased a new stake in United Therapeutics during the 3rd quarter worth $444,000. Simplify Asset Management Inc. acquired a new position in United Therapeutics in the 3rd quarter worth $8,351,000. Finally, Osaic Holdings Inc. boosted its position in United Therapeutics by 271.0% in the 2nd quarter. Osaic Holdings Inc. now owns 46,082 shares of the biotechnology company's stock valued at $14,027,000 after buying an additional 33,662 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
